Funding Tracker/Biossil Labs
Asset purchase · Pharma & Drug Discovery · Canada
Biossil Labs: Asset purchase
Announced November 2, 2026
The round
The SignalBiossil acquired SYN-004 (ribaxamase), SYN-007 and certain SYN-006 assets from Theriva Biologics. Closed October 30, 2026, with $350,000 upfront, up to $3 million in regulatory and $88 million in sales milestones, plus low single-digit royalties capped at $250 million. Milestones and royalties are contingent, not cash paid at closing.
What Biossil Labs does
AI-native biopharmaceutical company advancing clinical-stage drug candidates.
Biossil combines AI with clinical and translational development expertise, with teams in Toronto and Boston. In a transaction closed October 30 and announced November 2, 2026, it acquired Theriva Biologics rights to SYN-004 and SYN-007 and certain SYN-006 assets. These are development-stage programs, not approved treatments.
Full Biossil Labs profile- Company
- Biossil Labs
- Upfront payment
- $350K
- Stage
- Asset purchase
- Announced
- November 2, 2026
- Led by
- Not disclosed
- Vertical
- Pharma & Drug Discovery
- Country
- Canada
- Headquarters
- Toronto, Canada